Eleven Therapeutics

Eleven Therapeutics is a biotechnology company developing advanced RNA interference therapeutics designed to silence disease-causing genes, operating across multiple research hubs in Cambridge, Boston, and Tel Aviv. The startup focuses on creating scalable processes for programming precise, durable small interfering RNA molecules, with an initial clinical pipeline targeting severe respiratory diseases at their biological root cause. Operating with fewer than 25 employees and generating under $5 million in annual revenue, the enterprise has secured $22 million in total venture capital funding to advance its proprietary drug discovery platform. To accelerate its research and custom oligonucleotide synthesis capabilities, the firm maintains strategic development partnerships with prominent industry and academic institutions, including Twist Biosciences, the NIAID Vaccine Research Center, Biotage, and Cambridge University. Eleven Therapeutics was officially founded in 2020 by co-founders Yaniv Erlich and Shaul Ilan.

High-Level Overview

Eleven Therapeutics is a biotechnology company developing next-generation RNA therapeutics, particularly siRNA treatments for respiratory diseases, by integrating AI, combinatorial chemistry, and advanced RNA biology.[1][2][3] Founded in 2020 and headquartered in Tel Aviv, Israel, with hubs in Cambridge (UK), Boston (US), and Tel Aviv, it targets unmet needs in antiviral prophylactics and non-infectious respiratory conditions, such as an intranasal siRNA for SARS-CoV-2 in preclinical stages.[1][2][3] The company's discovery engine combines bio-engineering, genomics, and machine learning to map vast RNA combinatorial spaces, transforming drug discovery into a programmable process while serving patients with high unmet medical needs.[2][3]

Origin Story

Eleven Therapeutics was established in 2020 by founders Shaun Ilan, Greg Hannon, and Erlich Yaniv, a cross-disciplinary team of entrepreneur-scientists from leading academic institutions, pharma companies, and military backgrounds.[1][3] The idea emerged amid a biological revolution—driven by massively parallel DNA synthesis, high-throughput sequencing, genomic discoveries, and machine learning—aiming to replace slow trial-and-error drug development with scalable RNA programming.[3] Early traction includes partnerships with top institutions like the NIAID Vaccine Research Center, Cambridge University, Twist Biosciences, and Biotage, plus a preclinical pipeline focused on respiratory diseases.[1][3]

Core Differentiators

• Programmable RNA Discovery Engine: Orchestrates AI, massively parallel functional assays, combinatorial chemistry, and state-of-the-art RNA biology to efficiently map and program precise RNA molecules, silencing disease-causing genes at the root cause.[1][2][3]
• Multi-Geography Talent and Operations: Draws world-class expertise across Cambridge (UK), Boston (US), and Tel Aviv (Israel) hubs, fostering diversity, inclusion, and access to top talent pools.[2][3]
• Respiratory-Focused Pipeline: Rapidly expanding portfolio targets respiratory diseases, including preclinical intranasal siRNA for coronavirus infections, with emphasis on durable, tailor-made therapeutics.[1][2][3]
• Proven Team Track Record: Founders and team bring breakthroughs in RNA innovations, therapeutic R&D, and high-stakes environments, enabling efficient scaling from discovery to development.[2][3]

Role in the Broader Tech Landscape

Eleven Therapeutics rides the RNA therapeutics wave, amplified by post-COVID advances in mRNA vaccines and oligonucleotide drugs, leveraging AI and high-throughput technologies to accelerate beyond traditional trial-and-error methods.[2][3] Timing is ideal amid rising respiratory disease burdens—from pandemics to chronic conditions—where market forces like genomic data explosion and machine learning favor programmable, precise therapies over broad-spectrum drugs.[1][3] By partnering with institutions like NIAID and Cambridge University, it influences the ecosystem, pushing RNAi into scalable, next-gen applications and potentially reshaping biotech's approach to gene silencing for unmet needs.[3]

Quick Take & Future Outlook

Eleven Therapeutics is poised to expand its preclinical pipeline into clinical stages, prioritizing respiratory antivirals and non-infectious treatments amid growing AI-biotech convergence.[1][2] Trends like advancing combinatorial chemistry and global health threats will propel its programmable platform, potentially yielding durable prophylactics and first-in-class therapies. Its influence may evolve by setting standards for AI-driven RNA design, drawing more partnerships and investment to solidify its role in precision medicine—ushering RNA technologies from revolution to routine.